medigraphic.com
ISSN 1561-2937 (Print)

2020, Number 4

<< Back Next >>

Rev Cubana Cardiol Cir Cardiovasc 2020; 26 (4)

Percutaneous left atrial appendage occlusion in the nonvalvular atrial fibrillation

Obregón SA, Aroche AR, Aldama PL, Pérez BA, Castro AA, Vila GE

Language: Spanish
References: 10
Page: 1-4
PDF size: 192.96 Kb.


ABSTRACT

Though the non valvular atrial fibrillation is one of the most frequent diseases in our society, its prevalence will increase in the coming years because of the progressive aging of the population. The percutaneous closure of the left atrial appendage is an alternative for patients with non valvular atrial fibrillation and contra-indication to the treatment with anticoagulants. The closure of the left appendage is a secure and efficacious procedure. In the future, the closure of the left appendage could be an alternative to the treatment with anticoagulants for all the patients with non valvular atrial fibrillation. We present a patient with a contra-indication to the anticoagulants that received an implant of a Watchman closure device with a favourable evolution four years after the procedure.


REFERENCES

  1. Naccarelli GV, Varker H, Lim J, Schulman Kl. Increansing prevalence atrial fibrillation and flutter and United States. Am J. Cardiology 2009;104:1534-9.

  2. Gómez-Doblas JJ, Muñiz J, Alonso Martín JJ, et al. Prevalence of atrial fibrillation in Spain. OFRECE study results. Rev Esp Cardiol. 2014;67:259-69.

  3. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med 2009;361:1139-51.

  4. Holmes DR, Reddy VY, Turi ZG, et al. PROTECT AF. Investigators . Percutaneous closure of the Left atrial appendage versus warfarina therapy for prevention of stroke in patients with atrial fibrillation: a randomized non-inferioty trial. Lancet. 2009; 374:534-42.

  5. Nieuwlaat R, Capucci A, Camm AJ et al. Atrial fibrillation survey in ESC member countries: the Euro Heart Survey on atrial fibrillation. Eur Heart J 2005;26:2422-34.

  6. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH,et al 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythim Association Europace 2012;14:1385-413

  7. Sachin J, Shah et al. Net Clinical Benefit of oral Anticoagulation among older adults with atrial fibrillation. Cir Cardiovasc Qual Outcomes. 2019;12 (11) e 006212.

  8. Vivek Y, Reddy et al. 5 Year Outcomes Left Atrial Appendage Closure. From the PREVAIL and PROTECT FA Trial. J Am Coll Cardiol 2017;70(24):2964-75.

  9. Xavier Freixa y Victoria Martin Yuste. Cierre percutáneo de la orejuela izquierda. Rev Esp Cardiol, 2013;66(12):919-922

  10. William Whang, David R Holmes, Marc A. Miller, Marie-Noelle Langan, Subbrao Choudry, Aamir Sofi et al. Does Left Atrial Appendage Closure Reduce Mortality? A Vital Status Analysis of the Randomized PROTEC AF and PREVAIL Clinical Trials




2020     |     www.medigraphic.com